Home Biotechnology Vallon Pharmaceuticals
V

Vallon Pharmaceuticals

Profile managed by Bizz Id
Estados Unidos 11-50 employees
Biotechnology
Claim this profile

Description

Vallon Pharmaceuticals (NASDAQ: VLON) was a clinical-stage biopharmaceutical company focused on abuse-deterrent CNS disorder medications. Lead program ADAIR, a novel oral immediate-release dextroamphetamine formulation with abuse deterrence for ADHD/narcolepsy, failed to meet statistical significance in the pivotal Phase 3 SEAL trial.

Contact company

Register for free to see this company’s contact details and get in touch.

Register - Free

We only use technical cookies that are necessary for the site to work and to keep you signed in. We do not use analytics or advertising cookies. Cookies